Compare CRON & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRON | NVCR |
|---|---|---|
| Founded | N/A | 2000 |
| Country | Canada | Switzerland |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.2B |
| IPO Year | 2015 | 2015 |
| Metric | CRON | NVCR |
|---|---|---|
| Price | $2.59 | $11.85 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $28.08 |
| AVG Volume (30 Days) | ★ 1.8M | 964.3K |
| Earning Date | 05-11-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 21.79 |
| EPS | ★ N/A | N/A |
| Revenue | $146,587,000.00 | ★ $655,353,000.00 |
| Revenue This Year | $26.34 | $7.72 |
| Revenue Next Year | $15.53 | $6.74 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 24.63 | 8.28 |
| 52 Week Low | $1.81 | $9.82 |
| 52 Week High | $3.43 | $20.05 |
| Indicator | CRON | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 47.55 | 48.89 |
| Support Level | $2.45 | $10.72 |
| Resistance Level | $2.73 | $13.30 |
| Average True Range (ATR) | 0.14 | 0.58 |
| MACD | -0.00 | 0.05 |
| Stochastic Oscillator | 9.46 | 52.35 |
Cronos Group Inc headquartered in Toronto, Canada, cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis primarily to Israel. In the U.S., the company has an option to acquire 5.9% of U.S. multistate operator PharmaCann on a fully diluted basis upon easing of federal prohibition.
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.